Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences››2021,Vol. 42››Issue (11): 801-806.DOI:10.3969/j.issn.2097-0005.2021.11.001
• Basic Researches •Next Articles
Ping Yuan(), Xu Zhang, Baolu Tang, Xiaoyu Qi, Mingyue Ma, Shuguo Zheng(
)
Received:
2021-05-25Online:
2021-11-25Published:
2021-12-31Contact:
Shuguo Zheng袁萍(), 张旭, 唐保露, 戚小宇, 马明悦, 郑书国(
)
通讯作者:
郑书国作者简介:
袁萍,硕士研究生,研究方向:临床药理学,E-mail:740331265@qq.com。基金资助:
CLC Number:
Ping Yuan, Xu Zhang, Baolu Tang, Xiaoyu Qi, Mingyue Ma, Shuguo Zheng. Effect of Sijunzi granules on STC-1 cell apoptosis induced by palmitic acid[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2021, 42(11): 801-806.
袁萍, 张旭, 唐保露, 戚小宇, 马明悦, 郑书国. 四君子颗粒抑制棕榈酸诱导的STC-1细胞凋亡[J]. betway必威登陆网址 (betway.com )学报, 2021, 42(11): 801-806.
组别 | 剂量(g·kg-1) | 细胞活力(OD450) |
---|---|---|
对照组 | 1.11 ± 0.14 | |
模型组 | 0.49 ± 0.10** | |
空白血清对照组 | 0.47 ± 0.09** | |
SJZ (L) | 5.25 | 0.65 ± 0.05# |
SJZ (H) | 10.50 | 0.80 ± 0.09## |
F | 42.339 | |
P | < 0.001 |
组别 | 剂量(g·kg-1) | 细胞活力(OD450) |
---|---|---|
对照组 | 1.11 ± 0.14 | |
模型组 | 0.49 ± 0.10** | |
空白血清对照组 | 0.47 ± 0.09** | |
SJZ (L) | 5.25 | 0.65 ± 0.05# |
SJZ (H) | 10.50 | 0.80 ± 0.09## |
F | 42.339 | |
P | < 0.001 |
组别 | 剂量(g·kg-1) | 细胞凋亡率(%) |
---|---|---|
对照组 | 11.83 ± 1.5 | |
模型组 | 46.03 ± 5.2** | |
空白血清对照组 | 43.7 ± 6.68* | |
SJZ (L) | 5.25 | 34.16 ± 4.55# |
SJZ (H) | 10.50 | 27.44 ± 3.97## |
F | 34.601 | |
P | < 0.001 |
组别 | 剂量(g·kg-1) | 细胞凋亡率(%) |
---|---|---|
对照组 | 11.83 ± 1.5 | |
模型组 | 46.03 ± 5.2** | |
空白血清对照组 | 43.7 ± 6.68* | |
SJZ (L) | 5.25 | 34.16 ± 4.55# |
SJZ (H) | 10.50 | 27.44 ± 3.97## |
F | 34.601 | |
P | < 0.001 |
组别 | 剂量 (g·kg-1) | caspase-3 (U·mg-1prot) | caspase-9 (U·mg-1prot) |
---|---|---|---|
对照组 | 11.84 ± 2.32 | 15.94 ± 2.74 | |
模型组 | 26.1 ± 4.1** | 31.6 ± 2** | |
空白血清对照组 | 26.38 ± 1.72** | 31.24 ± 2.44** | |
SJZ (L) | 5.25 | 20.49 ± 1.19# | 25.01 ± 3.33## |
SJZ (H) | 10.50 | 17.29 ± 1.5## | 20.35 ± 1.86## |
F | 39.307 | 43.532 | |
P | < 0.001 | < 0.001 |
组别 | 剂量 (g·kg-1) | caspase-3 (U·mg-1prot) | caspase-9 (U·mg-1prot) |
---|---|---|---|
对照组 | 11.84 ± 2.32 | 15.94 ± 2.74 | |
模型组 | 26.1 ± 4.1** | 31.6 ± 2** | |
空白血清对照组 | 26.38 ± 1.72** | 31.24 ± 2.44** | |
SJZ (L) | 5.25 | 20.49 ± 1.19# | 25.01 ± 3.33## |
SJZ (H) | 10.50 | 17.29 ± 1.5## | 20.35 ± 1.86## |
F | 39.307 | 43.532 | |
P | < 0.001 | < 0.001 |
组别 | 剂量(g·kg-1) | p-PERK/ PERK | CHOP/β-actin |
---|---|---|---|
对照组 | 0.40 ± 0.06 | 0.40 ± 0.04 | |
模型组 | 0.81 ± 0.03** | 0.83 ± 0.03** | |
空白血清对照组 | 0.82 ± 0.05** | 0.82 ± 0.06** | |
SJZ (L) | 5.25 | 0.64 ± 0.05## | 0.56 ± 0.03## |
SJZ (H) | 10.50 | 0.56 ± 0.02## | 0.48 ± 0.05## |
F | 59.604 | 76.219 | |
P | < 0.001 | < 0.001 |
组别 | 剂量(g·kg-1) | p-PERK/ PERK | CHOP/β-actin |
---|---|---|---|
对照组 | 0.40 ± 0.06 | 0.40 ± 0.04 | |
模型组 | 0.81 ± 0.03** | 0.83 ± 0.03** | |
空白血清对照组 | 0.82 ± 0.05** | 0.82 ± 0.06** | |
SJZ (L) | 5.25 | 0.64 ± 0.05## | 0.56 ± 0.03## |
SJZ (H) | 10.50 | 0.56 ± 0.02## | 0.48 ± 0.05## |
F | 59.604 | 76.219 | |
P | < 0.001 | < 0.001 |
组别 | 剂量 (g·kg-1) | Bcl-2/β-actin | Bax/β-actin |
---|---|---|---|
对照组 | 0.72 ± 0.06 | 0.42 ± 0.06 | |
模型组 | 0.41 ± 0.04** | 0.83 ± 0.02** | |
空白血清对照组 | 0.40 ± 0.05** | 0.85 ± 0.08** | |
SJZ (L) | 5.25 | 0.52 ± 0.04# | 0.69 ± 0.06# |
SJZ (H) | 10.50 | 0.59 ± 0.09# | 0.48 ± 0.02## |
F | 19.617 | 52.739 | |
P | < 0.001 | < 0.001 |
组别 | 剂量 (g·kg-1) | Bcl-2/β-actin | Bax/β-actin |
---|---|---|---|
对照组 | 0.72 ± 0.06 | 0.42 ± 0.06 | |
模型组 | 0.41 ± 0.04** | 0.83 ± 0.02** | |
空白血清对照组 | 0.40 ± 0.05** | 0.85 ± 0.08** | |
SJZ (L) | 5.25 | 0.52 ± 0.04# | 0.69 ± 0.06# |
SJZ (H) | 10.50 | 0.59 ± 0.09# | 0.48 ± 0.02## |
F | 19.617 | 52.739 | |
P | < 0.001 | < 0.001 |
1 | Stolar M. Glycemic control and complications in type 2 diabetes mellitus[J]. Am J Med, 2010, 123(3): S3. |
2 | Turner RC, Cull CA, Frighi V, et al. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group[J]. JAMA, 1999, 281(21): 2005. |
3 | Müller TD, Finan B, Bloom SR, et al. Glucagon-like peptide 1 (GLP-1)[J]. Mol Metab, 2019, 30: 72. |
4 | Ahrén B. Incretin dysfunction in type 2 diabetes: clinical impact and future perspectives[J]. Diabetes Metab, 2013, 39(3): 195. |
5 | 黄杰, 徐云生, 黄延芹. 基于“脾虚致消”理论探讨健脾清热法通过AMPK/mTORC1/SAD-A通路防治糖尿病机制研究设想[J]. 中华中医药杂志, 2019, 34(3): 1104. |
6 | 何雪薇, 胡齐鸣. 健脾益气化湿法对2型糖尿病(脾虚夹湿型)患者GLP-1的影响[J]. 辽宁中医杂志, 2014, 41(9): 1903. |
7 | Arden C. A role for Glucagon-Like Peptide-1 in the regulation of β-cell autophagy[J]. Peptides, 2018, 100: 85. |
8 | Tian LL, Jin TR. The incretin hormone GLP-1 and mechanisms underlying its secretion[J]. J Diabetes, 2016, 8(6): 753. |
9 | Toft-Nielsen MB, Damholt MB, Madsbad S, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients[J]. J Clin Endocrinol Metab, 2001, 86(8): 3717. |
10 | Hayashi H, Yamada R, Das SS, et al. Glucagon-like peptide-1 production in the GLUTag cell line is impaired by free fatty acids via endoplasmic reticulum stress[J]. Metabolism, 2014, 63(6): 800. |
11 | Pandey VK, Mathur A, Kakkar P. Emerging role of Unfolded Protein Response (UPR) mediated proteotoxic apoptosis in diabetes[J]. Life Sci, 2019, 216: 246. |
12 | Li YM, Guo YS, Tang J, et al. New insights into the roles of CHOP-induced apoptosis in ER stress[J]. Acta Biochim Biophys Sin (Shanghai), 2014, 46(8): 629. |
13 | Chen Z, Lei L, Wen D, et al. Melatonin attenuates palmitic acid-induced mouse granulosa cells apoptosis via endoplasmic reticulum stress[J]. J Ovarian Res, 2019, 12(1): 43. |
14 | Zhang J, Wang XL, Liu H, et al. TNF-α enhances apoptosis by promoting chop expression in nucleus pulposus cells: role of the MAPK and NF-κB pathways[J]. J Orthop Res, 2019, 37(3): 697. |
[1] | Sen WANG, Yixin ZHANG, Yuli ZHAO, Huimin GUO, Li FENG.Research progress of ultrasound in the diagnosis of Metabolic associated fatty liver disease and related diseases[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2023, 44(9): 691-695. |
[2] | Yuxin HANG, Jiaqi YU, Yanfeng CAO, Ning XU, Jinglin LIU, Liang XU.Exploring the mechanism of Mongolian medicine of Fanbaicao in treatment of type 2 Diabetes Mellitus based on network pharmacology[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2023, 44(3): 191-196. |
[3] | Haoyang GUO, Wei WANG, Xin CHANG, Yuelong JIN, Hui YUAN.A two-sample Mendelian randomized study of the rheumatoid arthritis and risk of type 2 diabetes[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2022, 43(9): 703-706. |
[4] | Feng YUE, Yun GAO, Wen LIU, Shujing ZHANG.The relationship between total cholesterol level and bone metabolism in young and middle-aged patients with type 2 diabetes[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2022, 43(8): 605-608. |
[5] | Hui SUN, Hongxia HANG.The effect of community health management on elderly patients with impaired fasting glucose[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2022, 43(7): 529-533. |
[6] | Huihui LI, Yunling LIU.The relationship between 25-hydroxyvitamin D and depression in elderly T2DM patients with hypertension[J]. Journal of Shandong First Medical Unversity & Shandong Academy of Medical Sciences, 2022, 43(5): 353-359. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||